In Vivo and In Vitro Pro-Fibrotic Response of Lung-Resident Mesenchymal Stem Cells from Patients with Idiopathic Pulmonary Fibrosis

In Vivo and In Vitro Pro-Fibrotic Response of Lung-Resident Mesenchymal Stem Cells from Patients with Idiopathic Pulmonary Fibrosis

Lung-resident mesenchymal stem cells (LR-MSC) are thought to participate in idiopathic pulmonary fibrosis (IPF) by differentiating into myofibroblasts. On the other hand, LR-MSC in IPF patients present senescence-related features. It is unclear how they respond to a profibrotic environment. Here, we...

Full description

Bibliographic Details
Main Authors:	Gabriel Escarrer-Garau, Aina Martín-Medina, Joan Truyols-Vives, Cristina Gómez-Bellvert, Linda Elowsson, Gunilla Westergren-Thorsson, Maria Molina-Molina, Josep Mercader-Barceló, Ernest Sala-Llinàs
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Series:	Cells
Subjects:	idiopathic pulmonary fibrosis lung-resident mesenchymal stem cell transforming growth factor β bleomycin inflammation extracellular matrix proteins
Online Access:	https://www.mdpi.com/2073-4409/13/2/160

Similar Items

Mitochondrial Dysfunction in Lung Resident Mesenchymal Stem Cells from Idiopathic Pulmonary Fibrosis Patients
by: Josep Mercader-Barceló, et al.
Published: (2023-08-01)

Insights into the Role of Bioactive Food Ingredients and the Microbiome in Idiopathic Pulmonary Fibrosis
by: Josep Mercader-Barceló, et al.
Published: (2020-08-01)

Distal Lung Microenvironment Triggers Release of Mediators Recognized as Potential Systemic Biomarkers for Idiopathic Pulmonary Fibrosis
by: Dimitrios Kalafatis, et al.
Published: (2021-12-01)

The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models
by: Young-Suk Kim, et al.
Published: (2019-07-01)

Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats
by: Arian Amirkhosravi, et al.
Published: (2024-04-01)

Macrophage‐based delivery of anti‐fibrotic proteins alleviates bleomycin‐induced pulmonary fibrosis in mice
by: Huiying Liu, et al.
Published: (2023-09-01)

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis
by: Gali Epstein Shochet, et al.
Published: (2021-03-01)

Acute exacerbation of idiopathic pulmonary fibrosis model in the rats using bleomycin and lipopolysaccharides
by: Sandy Vitria Kurniawan, et al.
Published: (2023-06-01)

Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis
by: Youhei Takahashi, et al.
Published: (2018-02-01)

Plumbagin attenuates Bleomycin-induced lung fibrosis in mice
by: Saber Mehdizadeh, et al.
Published: (2022-10-01)

Dipeptidyl peptidase 4 expression is not associated with an activated fibroblast phenotype in idiopathic pulmonary fibrosis
by: Måns Kadefors, et al.
Published: (2022-08-01)

Surgical management of idiopathic torticollis secondary to a fibrotic band
by: Christopher David Jones, et al.
Published: (2012-09-01)

Prolyl oligopeptidase inhibition ameliorates experimental pulmonary fibrosis both in vivo and in vitro
by: Laura Cucinotta, et al.
Published: (2023-08-01)

Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
by: Sun Young Kyung, et al.
Published: (2018-04-01)

Evaluation of microRNA expression in a sheep model for lung fibrosis
by: Udari Eshani Perera, et al.
Published: (2021-11-01)

Enhanced Bruton’s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis
by: Peter Heukels, et al.
Published: (2019-10-01)

Transcriptional Profiling of Insulin-like Growth Factor Signaling Components in Embryonic Lung Development and Idiopathic Pulmonary Fibrosis
by: Vahid Kheirollahi, et al.
Published: (2022-06-01)

A case of bleomycin-induced lung toxicity
by: Cuneyt Tetikkurt, et al.
Published: (2018-11-01)

Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease
by: Chongxu Zhang, et al.
Published: (2020-10-01)

Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants
by: Logan Mlakar, et al.
Published: (2022-11-01)

Immune Mechanisms of Pulmonary Fibrosis with Bleomycin
by: Yuko Ishida, et al.
Published: (2023-02-01)

A novel pulmonary fibrosis murine model with immune‐related liver injury
by: Kexin Jia, et al.
Published: (2023-06-01)

Atractylodin ameliorates bleomycin-induced pulmonary inflammation and fibrosis in mice
by: Zhenhui Wu, et al.
Published: (2023-09-01)

Cell Therapy in Idiopathic Pulmonary Fibrosis†
by: Anna Serrano-Mollar
Published: (2018-08-01)

2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside ameliorates bleomycin-induced pulmonary fibrosis via regulating pro-fibrotic signaling pathways
by: Tsung-Teng Huang, et al.
Published: (2022-10-01)

Bleomycin electrosclerotherapy (BEST) for the treatment of vascular malformations. An International Network for Sharing Practices on Electrochemotherapy (InspECT) study group report
by: Muir Tobian, et al.
Published: (2023-06-01)

Anti-Fibrotic Effects of Low Toxic Microcystin-RR on Bleomycin-Induced Pulmonary Fibrosis: A Comparison with Microcystin-LR
by: Jie Wang, et al.
Published: (2021-06-01)

The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo
by: Stephanie Arndt, et al.
Published: (2021-10-01)

Experimental Models of Pulmonary Fibrosis and their Translational Potential
by: Jana Adamcakova, et al.
Published: (2019-12-01)

Dynamic Observation of Autophagy and Transcriptome Profiles in a Mouse Model of Bleomycin-Induced Pulmonary Fibrosis
by: Yani Wang, et al.
Published: (2021-07-01)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
by: Timothy M. Dempsey, et al.
Published: (2022-01-01)

The IL-33:ST2 axis is unlikely to play a central fibrogenic role in idiopathic pulmonary fibrosis
by: Katherine E. Stephenson, et al.
Published: (2023-03-01)

MicroRNA-124-3p alleviates repetitive bleomycin induced idiopathic pulmonary fibrosis in mouse by repressing Wnt/β-catenin signaling component AXIN1
by: Dharma Jaggi, et al.
Published: (2023-09-01)

Treatment of Verruca Vulgaris in Both External Auditory Canals Using Bleomycin Injections
by: Jun Hee Lee, et al.
Published: (2015-09-01)

Pulmonary Protein Oxidation and Oxidative Stress Modulation by <i>Lemna minor</i> L. in Progressive Bleomycin-Induced Idiopathic Pulmonary Fibrosis
by: Yanka Karamalakova, et al.
Published: (2022-03-01)

Losartan enhances the suppressive effect of pirfenidone on the bleomycin-induced epithelial-mesenchymal transition and oxidative stress in A549 cell line
by: Arian Amirkhosravi, et al.
Published: (2023-08-01)

In vivo pharmacokinetic and pharmacodynamic study of co-spray-dried inhalable pirfenidone microparticles in rats
by: Ji-Hyun Kang, et al.
Published: (2022-12-01)

Bleomycin Inhibits Proliferation via Schlafen-Mediated Cell Cycle Arrest in Mouse Alveolar Epithelial Cells
by: Soojin Jang, M.S., et al.
Published: (2019-04-01)

Glutamyl-Prolyl-tRNA Synthetase Regulates Epithelial Expression of Mesenchymal Markers and Extracellular Matrix Proteins: Implications for Idiopathic Pulmonary Fibrosis
by: Dae-Geun Song, et al.
Published: (2018-11-01)

Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
by: Anna Valeria Samarelli, et al.
Published: (2021-08-01)